Literatur zu

Pharmakotherapie
Kardiovaskuläre Nebenwirkungen von klassischen NSAR und Coxiben

Henning Lange • Leopold Eberhart

1 Bolten WW, Lang B, Wagner AV, Krobot KJ. Konsequenzen und Kosten der NSAR-Gastropathie in Deutschland. Akt Rheumatol 1999; 24: 127-134


5 Bombardier C, Laine L, Reicin A. et al.. Comparison of upper gastrointestinal


12 Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Soren F,

13 Singh G, Mithal A, Triadafilopoulos G. Both selective and non selective cox-2 inhibitors and non selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Annals Rheum Dis 2005; 64:


18 Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program cardiovascular outcomes with etoricoxib vs. diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006; 152:
